SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells $37,466.25 in Stock

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) CFO Anshul Maheshwari sold 2,425 shares of the business's stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $15.45, for a total transaction of $37,466.25. Following the sale, the chief financial officer now directly owns 205,516 shares of the company's stock, valued at approximately $3,175,222.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

SI-BONE Price Performance

SIBN stock traded down $0.45 on Thursday, hitting $15.40. 310,038 shares of the company's stock traded hands, compared to its average volume of 458,985. SI-BONE, Inc. has a 1-year low of $14.88 and a 1-year high of $29.51. The stock has a market cap of $632.32 million, a price-to-earnings ratio of -13.51 and a beta of 1.20. The stock has a fifty day moving average of $18.31 and a 200-day moving average of $18.81. The company has a current ratio of 9.01, a quick ratio of 8.15 and a debt-to-equity ratio of 0.21.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, February 26th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.02. SI-BONE had a negative net margin of 31.20% and a negative return on equity of 28.22%. The business had revenue of $38.86 million during the quarter, compared to analyst estimates of $38.60 million. On average, analysts forecast that SI-BONE, Inc. will post -0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Piper Sandler assumed coverage on shares of SI-BONE in a research report on Thursday, March 28th. They issued an "overweight" rating and a $25.00 target price for the company. Truist Financial reiterated a "buy" rating and issued a $24.00 price objective (down from $26.00) on shares of SI-BONE in a report on Tuesday, February 27th. Needham & Company LLC reiterated a "buy" rating and issued a $27.00 price objective on shares of SI-BONE in a report on Wednesday. Morgan Stanley increased their price objective on shares of SI-BONE from $25.00 to $26.00 and gave the company an "overweight" rating in a report on Tuesday, February 27th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of SI-BONE in a report on Tuesday, February 27th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, SI-BONE presently has a consensus rating of "Buy" and a consensus price target of $26.67.

Institutional Trading of SI-BONE

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brown Advisory Inc. lifted its stake in SI-BONE by 5.4% during the fourth quarter. Brown Advisory Inc. now owns 4,207,703 shares of the company's stock valued at $88,320,000 after purchasing an additional 214,089 shares during the last quarter. BlackRock Inc. lifted its stake in SI-BONE by 10.6% during the second quarter. BlackRock Inc. now owns 3,041,535 shares of the company's stock valued at $82,061,000 after purchasing an additional 291,111 shares during the last quarter. First Light Asset Management LLC lifted its position in shares of SI-BONE by 0.9% in the 4th quarter. First Light Asset Management LLC now owns 2,547,392 shares of the company's stock valued at $53,470,000 after acquiring an additional 23,299 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of SI-BONE by 4.8% in the 4th quarter. Vanguard Group Inc. now owns 2,419,831 shares of the company's stock valued at $50,792,000 after acquiring an additional 111,315 shares in the last quarter. Finally, Granahan Investment Management LLC lifted its position in shares of SI-BONE by 13.2% in the 4th quarter. Granahan Investment Management LLC now owns 1,286,450 shares of the company's stock valued at $27,003,000 after acquiring an additional 150,217 shares in the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.